Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Prognostic models turn the Heat(IT)up on FLT3ITD-mutated AML.

Gallipoli P, Huntly BJ.

Clin Cancer Res. 2018 Nov 2. pii: clincanres.3146.2018. doi: 10.1158/1078-0432.CCR-18-3146. [Epub ahead of print]

PMID:
30389660
2.

Intratumoral Heterogeneity: Tools to Understand and Exploit Clone Wars in AML.

Giotopoulos G, Huntly BJP.

Cancer Cell. 2018 Oct 8;34(4):533-535. doi: 10.1016/j.ccell.2018.09.004.

PMID:
30300577
3.

Population dynamics of normal human blood inferred from somatic mutations.

Lee-Six H, Øbro NF, Shepherd MS, Grossmann S, Dawson K, Belmonte M, Osborne RJ, Huntly BJP, Martincorena I, Anderson E, O'Neill L, Stratton MR, Laurenti E, Green AR, Kent DG, Campbell PJ.

Nature. 2018 Sep;561(7724):473-478. doi: 10.1038/s41586-018-0497-0. Epub 2018 Sep 5.

PMID:
30185910
4.

Hematopoietic stem cells made BETter by inhibition.

Marando L, Huntly BJP.

Haematologica. 2018 Jun;103(6):919-921. doi: 10.3324/haematol.2018.193706. No abstract available.

5.

UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.

Gozdecka M, Meduri E, Mazan M, Tzelepis K, Dudek M, Knights AJ, Pardo M, Yu L, Choudhary JS, Metzakopian E, Iyer V, Yun H, Park N, Varela I, Bautista R, Collord G, Dovey O, Garyfallos DA, De Braekeleer E, Kondo S, Cooper J, Göttgens B, Bullinger L, Northcott PA, Adams D, Vassiliou GS, Huntly BJP.

Nat Genet. 2018 Jun;50(6):883-894. doi: 10.1038/s41588-018-0114-z. Epub 2018 May 7.

PMID:
29736013
6.

Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.

Gallipoli P, Giotopoulos G, Tzelepis K, Costa ASH, Vohra S, Medina-Perez P, Basheer F, Marando L, Di Lisio L, Dias JML, Yun H, Sasca D, Horton SJ, Vassiliou G, Frezza C, Huntly BJP.

Blood. 2018 Apr 12;131(15):1639-1653. doi: 10.1182/blood-2017-12-820035. Epub 2018 Feb 20.

7.

Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors.

Booth CAG, Barkas N, Neo WH, Boukarabila H, Soilleux EJ, Giotopoulos G, Farnoud N, Giustacchini A, Ashley N, Carrelha J, Jamieson L, Atkinson D, Bouriez-Jones T, Prinjha RK, Milne TA, Teachey DT, Papaemmanuil E, Huntly BJP, Jacobsen SEW, Mead AJ.

Cancer Cell. 2018 Feb 12;33(2):274-291.e8. doi: 10.1016/j.ccell.2018.01.006.

PMID:
29438697
8.

Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors.

Horton SJ, Giotopoulos G, Yun H, Vohra S, Sheppard O, Bashford-Rogers R, Rashid M, Clipson A, Chan WI, Sasca D, Yiangou L, Osaki H, Basheer F, Gallipoli P, Burrows N, Erdem A, Sybirna A, Foerster S, Zhao W, Sustic T, Petrunkina Harrison A, Laurenti E, Okosun J, Hodson D, Wright P, Smith KG, Maxwell P, Fitzgibbon J, Du MQ, Adams DJ, Huntly BJP.

Nat Cell Biol. 2017 Sep;19(9):1093-1104. doi: 10.1038/ncb3597. Epub 2017 Aug 21.

9.

Novel epigenetic therapies in hematological malignancies: Current status and beyond.

Gallipoli P, Huntly BJP.

Semin Cancer Biol. 2018 Aug;51:198-210. doi: 10.1016/j.semcancer.2017.07.005. Epub 2017 Aug 4. Review.

PMID:
28782607
10.

A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.

Beck D, Thoms JAI, Palu C, Herold T, Shah A, Olivier J, Boelen L, Huang Y, Chacon D, Brown A, Babic M, Hahn C, Perugini M, Zhou X, Huntly BJ, Schwarzer A, Klusmann JH, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Bohlander SK, To LB, Scott HS, Lewis ID, D'Andrea RJ, Wong JWH, Pimanda JE.

Leukemia. 2018 Feb;32(2):263-272. doi: 10.1038/leu.2017.210. Epub 2017 Jul 4.

PMID:
28674423
11.

Corrigendum: Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition.

Sciacovelli M, Gonçalves E, Johnson TI, Zecchini VR, da Costa AS, Gaude E, Drubbel AV, Theobald SJ, Abbo SR, Tran MG, Rajeeve V, Cardaci S, Foster S, Yun H, Cutillas P, Warren A, Gnanapragasam V, Gottlieb E, Franze K, Huntly B, Maher ER, Maxwell PH, Saez-Rodriguez J, Frezza C.

Nature. 2016 Dec 1;540(7631):150. doi: 10.1038/nature20144. Epub 2016 Oct 19. No abstract available.

PMID:
27760119
12.

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.

Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V, Li M, Mazan M, Gozdecka M, Ohnishi S, Cooper J, Patel M, McKerrell T, Chen B, Domingues AF, Gallipoli P, Teichmann S, Ponstingl H, McDermott U, Saez-Rodriguez J, Huntly BJP, Iorio F, Pina C, Vassiliou GS, Yusa K.

Cell Rep. 2016 Oct 18;17(4):1193-1205. doi: 10.1016/j.celrep.2016.09.079.

13.

A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation.

Kollmann K, Warsch W, Gonzalez-Arias C, Nice FL, Avezov E, Milburn J, Li J, Dimitropoulou D, Biddie S, Wang M, Poynton E, Colzani M, Tijssen MR, Anand S, McDermott U, Huntly B, Green T.

Leukemia. 2017 Apr;31(4):934-944. doi: 10.1038/leu.2016.280. Epub 2016 Oct 14.

14.

Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition.

Sciacovelli M, Gonçalves E, Johnson TI, Zecchini VR, da Costa AS, Gaude E, Drubbel AV, Theobald SJ, Abbo SR, Tran MG, Rajeeve V, Cardaci S, Foster S, Yun H, Cutillas P, Warren A, Gnanapragasam V, Gottlieb E, Franze K, Huntly B, Maher ER, Maxwell PH, Saez-Rodriguez J, Frezza C.

Nature. 2016 Aug 31;537(7621):544-547. doi: 10.1038/nature19353. Erratum in: Nature. 2016 Dec 1;540(7631):150.

15.

Mll-AF4 Confers Enhanced Self-Renewal and Lymphoid Potential during a Restricted Window in Development.

Barrett NA, Malouf C, Kapeni C, Bacon WA, Giotopoulos G, Jacobsen SEW, Huntly BJ, Ottersbach K.

Cell Rep. 2016 Jul 26;16(4):1039-1054. doi: 10.1016/j.celrep.2016.06.046. Epub 2016 Jul 7.

16.

Independence of epigenetic and genetic diversity in AML.

Sasca D, Huntly BJ.

Nat Med. 2016 Jul 7;22(7):708-9. doi: 10.1038/nm.4136. No abstract available.

PMID:
27387883
17.

Functional interdependence of BRD4 and DOT1L in MLL leukemia.

Gilan O, Lam EY, Becher I, Lugo D, Cannizzaro E, Joberty G, Ward A, Wiese M, Fong CY, Ftouni S, Tyler D, Stanley K, MacPherson L, Weng CF, Chan YC, Ghisi M, Smil D, Carpenter C, Brown P, Garton N, Blewitt ME, Bannister AJ, Kouzarides T, Huntly BJ, Johnstone RW, Drewes G, Dawson SJ, Arrowsmith CH, Grandi P, Prinjha RK, Dawson MA.

Nat Struct Mol Biol. 2016 Jul;23(7):673-81. doi: 10.1038/nsmb.3249. Epub 2016 Jun 13.

PMID:
27294782
18.

Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.

McKerrell T, Moreno T, Ponstingl H, Bolli N, Dias JM, Tischler G, Colonna V, Manasse B, Bench A, Bloxham D, Herman B, Fletcher D, Park N, Quail MA, Manes N, Hodkinson C, Baxter J, Sierra J, Foukaneli T, Warren AJ, Chi J, Costeas P, Rad R, Huntly B, Grove C, Ning Z, Tyler-Smith C, Varela I, Scott M, Nomdedeu J, Mustonen V, Vassiliou GS.

Blood. 2016 Jul 7;128(1):e1-9. doi: 10.1182/blood-2015-11-683334. Epub 2016 Apr 27.

19.

Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance.

Grimwade D, Ivey A, Huntly BJ.

Blood. 2016 Jan 7;127(1):29-41. doi: 10.1182/blood-2015-07-604496. Epub 2015 Dec 10. Review.

20.

BET inhibitor resistance emerges from leukaemia stem cells.

Fong CY, Gilan O, Lam EY, Rubin AF, Ftouni S, Tyler D, Stanley K, Sinha D, Yeh P, Morison J, Giotopoulos G, Lugo D, Jeffrey P, Lee SC, Carpenter C, Gregory R, Ramsay RG, Lane SW, Abdel-Wahab O, Kouzarides T, Johnstone RW, Dawson SJ, Huntly BJ, Prinjha RK, Papenfuss AT, Dawson MA.

Nature. 2015 Sep 24;525(7570):538-42. doi: 10.1038/nature14888. Epub 2015 Sep 14.

21.

A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression.

Giotopoulos G, van der Weyden L, Osaki H, Rust AG, Gallipoli P, Meduri E, Horton SJ, Chan WI, Foster D, Prinjha RK, Pimanda JE, Tenen DG, Vassiliou GS, Koschmieder S, Adams DJ, Huntly BJ.

J Exp Med. 2015 Sep 21;212(10):1551-69. doi: 10.1084/jem.20141661. Epub 2015 Aug 24.

22.

Somatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5(+/-) leukemia.

van der Weyden L, Giotopoulos G, Wong K, Rust AG, Robles-Espinoza CD, Osaki H, Huntly BJ, Adams DJ.

BMC Cancer. 2015 Aug 13;15:585. doi: 10.1186/s12885-015-1586-1.

23.

BET bromodomain inhibitors in leukemia.

Basheer F, Huntly BJ.

Exp Hematol. 2015 Aug;43(8):718-31. doi: 10.1016/j.exphem.2015.06.004. Epub 2015 Jul 9. Review.

PMID:
26163798
24.

Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia.

Gallipoli P, Giotopoulos G, Huntly BJ.

Ther Adv Hematol. 2015 Jun;6(3):103-19. doi: 10.1177/2040620715577614. Review.

25.

The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.

Giotopoulos G, Chan WI, Horton SJ, Ruau D, Gallipoli P, Fowler A, Crawley C, Papaemmanuil E, Campbell PJ, Göttgens B, Van Deursen JM, Cole PA, Huntly BJ.

Oncogene. 2016 Jan 21;35(3):279-89. doi: 10.1038/onc.2015.92. Epub 2015 Apr 20.

26.

The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors.

Pellicano F, Scott MT, Helgason GV, Hopcroft LE, Allan EK, Aspinall-O'Dea M, Copland M, Pierce A, Huntly BJ, Whetton AD, Holyoake TL.

Stem Cells. 2014 Sep;32(9):2324-37. doi: 10.1002/stem.1748.

27.

Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.

Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, Scholl C, Fröhling S.

Blood. 2014 Jul 3;124(1):13-23. doi: 10.1182/blood-2014-02-558114. Epub 2014 Apr 24.

28.

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR.

N Engl J Med. 2013 Dec 19;369(25):2391-2405. doi: 10.1056/NEJMoa1312542. Epub 2013 Dec 10.

29.

Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.

Dawson MA, Gudgin EJ, Horton SJ, Giotopoulos G, Meduri E, Robson S, Cannizzaro E, Osaki H, Wiese M, Putwain S, Fong CY, Grove C, Craig J, Dittmann A, Lugo D, Jeffrey P, Drewes G, Lee K, Bullinger L, Prinjha RK, Kouzarides T, Vassiliou GS, Huntly BJ.

Leukemia. 2014 Feb;28(2):311-20. doi: 10.1038/leu.2013.338. Epub 2013 Nov 13.

30.

BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms.

Wyspiańska BS, Bannister AJ, Barbieri I, Nangalia J, Godfrey A, Calero-Nieto FJ, Robson S, Rioja I, Li J, Wiese M, Cannizzaro E, Dawson MA, Huntly B, Prinjha RK, Green AR, Gottgens B, Kouzarides T.

Leukemia. 2014 Jan;28(1):88-97. doi: 10.1038/leu.2013.234. Epub 2013 Aug 9.

PMID:
23929215
31.

Network properties derived from deep sequencing of human B-cell receptor repertoires delineate B-cell populations.

Bashford-Rogers RJ, Palser AL, Huntly BJ, Rance R, Vassiliou GS, Follows GA, Kellam P.

Genome Res. 2013 Nov;23(11):1874-84. doi: 10.1101/gr.154815.113. Epub 2013 Jun 6.

32.

HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias.

Calero-Nieto FJ, Joshi A, Bonadies N, Kinston S, Chan WI, Gudgin E, Pridans C, Landry JR, Kikuchi J, Huntly BJ, Gottgens B.

Oncogene. 2013 Nov 28;32(48):5471-80. doi: 10.1038/onc.2013.175. Epub 2013 May 27.

33.

Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture.

Conte N, Varela I, Grove C, Manes N, Yusa K, Moreno T, Segonds-Pichon A, Bench A, Gudgin E, Herman B, Bolli N, Ellis P, Haddad D, Costeas P, Rad R, Scott M, Huntly B, Bradley A, Vassiliou GS.

Leukemia. 2013 Sep;27(9):1820-5. doi: 10.1038/leu.2013.117. Epub 2013 Apr 18.

34.

An unexpected finding after a fall from a horse.

Raby S, Greaves D, Padayatty J, Huntly B.

BMJ. 2013 Feb 12;346:f724. doi: 10.1136/bmj.f724. No abstract available.

PMID:
23403830
35.

Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia.

Diffner E, Beck D, Gudgin E, Thoms JA, Knezevic K, Pridans C, Foster S, Goode D, Lim WK, Boelen L, Metzeler KH, Micklem G, Bohlander SK, Buske C, Burnett A, Ottersbach K, Vassiliou GS, Olivier J, Wong JW, Göttgens B, Huntly BJ, Pimanda JE.

Blood. 2013 Mar 21;121(12):2289-300. doi: 10.1182/blood-2012-07-446120. Epub 2013 Jan 17. Erratum in: Blood. 2014 May 1;123(18):2901.

36.

Cancer stem cell definitions and terminology: the devil is in the details.

Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wöhrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C.

Nat Rev Cancer. 2012 Nov;12(11):767-75. doi: 10.1038/nrc3368. Epub 2012 Oct 11. Review.

PMID:
23051844
37.

Disordered signaling in myeloproliferative neoplasms.

Anand S, Huntly BJ.

Hematol Oncol Clin North Am. 2012 Oct;26(5):1017-35. doi: 10.1016/j.hoc.2012.07.004. Epub 2012 Aug 25. Review.

PMID:
23009935
38.

Detection of cytoplasmic nucleophosmin expression by imaging flow cytometry.

Grimwade L, Gudgin E, Bloxham D, Bottley G, Vassiliou G, Huntly B, Scott MA, Erber WN.

Cytometry A. 2012 Oct;81(10):896-900. doi: 10.1002/cyto.a.22116. Epub 2012 Sep 11.

39.

Targeting epigenetic readers in cancer.

Dawson MA, Kouzarides T, Huntly BJ.

N Engl J Med. 2012 Aug 16;367(7):647-57. doi: 10.1056/NEJMra1112635. Review. No abstract available.

PMID:
22894577
40.

Recent advances in acute myeloid leukemia stem cell biology.

Horton SJ, Huntly BJ.

Haematologica. 2012 Jul;97(7):966-74. doi: 10.3324/haematol.2011.054734. Epub 2012 Apr 17. Review.

41.

The transcriptional coactivator Cbp regulates self-renewal and differentiation in adult hematopoietic stem cells.

Chan WI, Hannah RL, Dawson MA, Pridans C, Foster D, Joshi A, Göttgens B, Van Deursen JM, Huntly BJ.

Mol Cell Biol. 2011 Dec;31(24):5046-60. doi: 10.1128/MCB.05830-11. Epub 2011 Oct 17.

42.

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM, Huthmacher C, Gudgin E, Lugo D, Beinke S, Chapman TD, Roberts EJ, Soden PE, Auger KR, Mirguet O, Doehner K, Delwel R, Burnett AK, Jeffrey P, Drewes G, Lee K, Huntly BJ, Kouzarides T.

Nature. 2011 Oct 2;478(7370):529-33. doi: 10.1038/nature10509.

43.

Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis.

Mduff FK, Hook CE, Tooze RM, Huntly BJ, Pandolfi PP, Turner SD.

Lab Invest. 2011 Sep;91(9):1298-303. doi: 10.1038/labinvest.2011.96. Epub 2011 Jun 27.

44.

Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms.

Anand S, Stedham F, Gudgin E, Campbell P, Beer P, Green AR, Huntly BJ.

Blood. 2011 Aug 11;118(6):1610-21. doi: 10.1182/blood-2011-02-335042. Epub 2011 Jun 8.

45.

Modeling the evolution of ETV6-RUNX1-induced B-cell precursor acute lymphoblastic leukemia in mice.

van der Weyden L, Giotopoulos G, Rust AG, Matheson LS, van Delft FW, Kong J, Corcoran AE, Greaves MF, Mullighan CG, Huntly BJ, Adams DJ.

Blood. 2011 Jul 28;118(4):1041-51. doi: 10.1182/blood-2011-02-338848. Epub 2011 May 31.

46.

Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms.

Anand S, Stedham F, Beer P, Gudgin E, Ortmann CA, Bench A, Erber W, Green AR, Huntly BJ.

Blood. 2011 Jul 7;118(1):177-81. doi: 10.1182/blood-2010-12-327593. Epub 2011 May 11.

47.

Acute myeloid leukemia: leukemia stem cells write a prognostic signature.

Gudgin EJ, Huntly BJ.

Stem Cell Res Ther. 2011 Apr 27;2(2):21. doi: 10.1186/scrt62.

48.

Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias.

Kvinlaug BT, Chan WI, Bullinger L, Ramaswami M, Sears C, Foster D, Lazic SE, Okabe R, Benner A, Lee BH, De Silva I, Valk PJ, Delwel R, Armstrong SA, Döhner H, Gilliland DG, Huntly BJ.

Cancer Res. 2011 Jun 15;71(12):4117-29. doi: 10.1158/0008-5472.CAN-11-0176. Epub 2011 Apr 19.

49.

Genome-wide analysis of transcriptional reprogramming in mouse models of acute myeloid leukaemia.

Bonadies N, Foster SD, Chan WI, Kvinlaug BT, Spensberger D, Dawson MA, Spooncer E, Whetton AD, Bannister AJ, Huntly BJ, Göttgens B.

PLoS One. 2011 Jan 28;6(1):e16330. doi: 10.1371/journal.pone.0016330.

50.

A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients.

Oram SH, Thoms JA, Pridans C, Janes ME, Kinston SJ, Anand S, Landry JR, Lock RB, Jayaraman PS, Huntly BJ, Pimanda JE, Göttgens B.

Oncogene. 2010 Oct 28;29(43):5796-808. doi: 10.1038/onc.2010.320. Epub 2010 Aug 2.

PMID:
20676125

Supplemental Content

Loading ...
Support Center